Sanofi SA (SASY)

85.13
+0.78(+0.92%)
  • Volume:
    1,331,113
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    84.28 - 85.16
  • Type:Equity
  • Market:France
  • ISIN:FR0000120578

SASY Overview

Prev. Close
84.35
Day's Range
84.28-85.16
Revenue
57.26B
Open
84.91
52 wk Range
74.92-91.14
EPS
4.92
Volume
1,331,113
Market Cap
106.1B
Dividend (Yield)
3.20
(3.79%)
Average Vol. (3m)
1,882,865
P/E Ratio
17.15
Beta
0.53
1-Year Change
0.9%
Shares Outstanding
1,255,273,146
Next Earnings Date
Feb 04, 2022
What is your sentiment on Sanofi SA?
or
Vote to see community's results!

Sanofi SA Company Profile

Employees
99412
Market
France

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
  • SASY is creating separate company Opella World Wide to separate CHC/OTC business. With standard business they may look for a merger. I think we could expect a merger with GSK.
    0
    • Indietro tutta con problemi legali!!!???
      0
      • Sanofi
        0
        • Vola occhio!!
          0
          • Sanofi Stuck as it’s not involved in the vaccine process; this is so disturbing
            1
            • Very good earnings, to the moonnnnnn
              2
              • sanofi will participate in the production of the pfizer vaccine !!! In addition to continuing with their own vaccine, which will be the safest of all due to the protocols they are following in the manufacture. Sanofi does not enter false advertisements and plays with the news on the stock market to enrich its managers. It is a much more reliable company than other pharmaceutical companies that are developing the vaccine.
                0
                • sanofi will participate in the production of the pfizer vaccine !!! In addition to continuing with their own vaccine, which will be the safest of all due to the protocols they are following in the manufacture. Sanofi does not enter false advertisements and plays with the news on the stock market to enrich its managers. It is a much more reliable company than other pharmaceutical companies that are developing the vaccine.
                  0
                  • Sanofi vaccine will arrive one year later at best. saying this is like saying they wasted money on nothing
                    0
                    • This is by far one of the largest vaccine makers in the world. Their experience suggests they have better chances than the others to find a more effective vaccine even if it takes longer to develop. Seems like a good point to buy.
                      0
                      • Really? Looks rather like the next big fall
                        0
                      • good point)))
                        0
                      • reading this today makes wonder why you didn’t become the next warren buffett...
                        0
                    • just acquired a new company: Principia Biopharma
                      0
                      • Is this a good time to buy this Stock?
                        0
                        • Dividends come in 5 days... Why are people selling?
                          0
                          • time to reach 100
                            1
                            • Incrementiamo??
                              1
                          • 0886193318 mình sẽ cung cấp  tập tin.  tin mình biết về thương vụ này cho bạn muốn tham gia kiếm lợi nhuận bên sàn mình cũng như kiến thức từ thị trường chứng khoán quốc tế
                            0
                            • are you in stock trading please ?
                              0
                            • hello .
                              0
                            • yes it's upward trend
                              0
                          • GOOD TIME TO BUY
                            3
                            • Why so ??
                              0
                            • Sanofi, close to agreement with the EU for 300 million doses of anti-COVID-19 vaccine
                              0
                          • Strong buy
                            0
                            • Nice jump up
                              0
                              • can drop up to 65
                                0
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.